LeMaitre Vascular, Inc. Logo

LeMaitre Vascular, Inc.

LMAT

(3.5)
Stock Price

90,18 USD

12.13% ROA

10.52% ROE

45x PER

Market Cap.

1.227.147.584,00 USD

5.85% DER

1.02% Yield

15.56% NPM

LeMaitre Vascular, Inc. Stock Analysis

LeMaitre Vascular, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

LeMaitre Vascular, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

2 DER

The stock has a minimal amount of debt (6%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

4 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

5 Dividend Growth

The company's dividend growth has exhibited a remarkable upward trend over the past five years, consistently delivering higher returns to investors.

6 Dividend

With a solid track record of dividend payments over the past five years, the company has established itself as a dependable choice for investors seeking consistent income.

7 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (424), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

8 ROE

The stock's ROE falls within an average range (9.28%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

9 PBV

The stock's high Price-to-Book Value (P/BV) ratio (4.16x) suggests it's overvalued, potentially making it an expensive investment.

10 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

11 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

LeMaitre Vascular, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

LeMaitre Vascular, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

LeMaitre Vascular, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

LeMaitre Vascular, Inc. Revenue
Year Revenue Growth
2001 12.550.000
2002 17.364.000 27.72%
2003 20.664.000 15.97%
2004 26.183.000 21.08%
2005 30.727.000 14.79%
2006 34.628.000 11.27%
2007 41.446.000 16.45%
2008 48.720.000 14.93%
2009 50.908.000 4.3%
2010 56.060.000 9.19%
2011 57.685.000 2.82%
2012 56.735.000 -1.67%
2013 64.549.000 12.11%
2014 71.097.000 9.21%
2015 78.352.000 9.26%
2016 89.151.000 12.11%
2017 100.867.000 11.62%
2018 105.568.000 4.45%
2019 117.232.000 9.95%
2020 129.366.000 9.38%
2021 154.424.000 16.23%
2022 161.651.000 4.47%
2023 189.644.000 14.76%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

LeMaitre Vascular, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2001 862.000
2002 1.295.000 33.44%
2003 0 0%
2004 2.120.000 100%
2005 3.015.000 29.68%
2006 3.301.000 8.66%
2007 4.591.000 28.1%
2008 5.328.000 13.83%
2009 5.910.000 9.85%
2010 5.488.000 -7.69%
2011 4.425.000 -24.02%
2012 5.092.000 13.1%
2013 5.243.000 2.88%
2014 4.671.000 -12.25%
2015 5.479.000 14.75%
2016 6.141.000 10.78%
2017 6.636.000 7.46%
2018 8.197.000 19.04%
2019 9.276.000 11.63%
2020 10.099.000 8.15%
2021 11.801.000 14.42%
2022 13.294.000 11.23%
2023 16.896.000 21.32%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

LeMaitre Vascular, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 7.105.000 100%
2007 28.977.000 75.48%
2008 9.999.000 -189.8%
2009 9.852.000 -1.49%
2010 10.506.000 6.23%
2011 11.228.000 6.43%
2012 10.973.000 -2.32%
2013 12.576.000 12.75%
2014 13.889.000 9.45%
2015 14.010.000 0.86%
2016 14.354.000 2.4%
2017 17.010.000 15.61%
2018 17.689.000 3.84%
2019 19.055.000 7.17%
2020 22.501.000 15.31%
2021 25.501.000 11.76%
2022 28.745.000 11.29%
2023 30.952.000 7.13%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

LeMaitre Vascular, Inc. EBITDA
Year EBITDA Growth
2001 -282.000
2002 833.000 133.85%
2003 20.664.000 95.97%
2004 2.882.000 -617%
2005 3.292.000 12.45%
2006 1.081.000 -204.53%
2007 -335.000 422.69%
2008 937.000 135.75%
2009 5.461.000 82.84%
2010 7.723.000 29.29%
2011 7.247.000 -6.57%
2012 3.744.000 -93.56%
2013 4.518.000 17.13%
2014 7.850.000 42.45%
2015 10.793.000 27.27%
2016 16.336.000 33.93%
2017 21.103.000 22.59%
2018 13.261.000 -59.14%
2019 21.183.000 37.4%
2020 28.196.000 24.87%
2021 36.622.000 23.01%
2022 30.597.000 -19.69%
2023 37.476.000 18.36%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

LeMaitre Vascular, Inc. Gross Profit
Year Gross Profit Growth
2001 7.717.000
2002 11.284.000 31.61%
2003 20.664.000 45.39%
2004 18.403.000 -12.29%
2005 21.800.000 15.58%
2006 25.261.000 13.7%
2007 30.707.000 17.74%
2008 33.903.000 9.43%
2009 37.304.000 9.12%
2010 41.719.000 10.58%
2011 40.227.000 -3.71%
2012 40.868.000 1.57%
2013 45.115.000 9.41%
2014 48.431.000 6.85%
2015 54.166.000 10.59%
2016 62.936.000 13.93%
2017 70.697.000 10.98%
2018 73.939.000 4.38%
2019 79.853.000 7.41%
2020 84.618.000 5.63%
2021 101.382.000 16.54%
2022 104.896.000 3.35%
2023 123.260.000 14.9%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

LeMaitre Vascular, Inc. Net Profit
Year Net Profit Growth
2001 -605.000
2002 483.000 225.26%
2003 -222.000 317.57%
2004 927.000 123.95%
2005 55.000 -1585.45%
2006 -1.172.000 104.69%
2007 -2.934.000 60.05%
2008 -3.314.000 11.47%
2009 1.598.000 307.38%
2010 6.013.000 73.42%
2011 2.143.000 -180.59%
2012 2.571.000 16.65%
2013 3.202.000 19.71%
2014 3.915.000 18.21%
2015 7.758.000 49.54%
2016 10.590.000 26.74%
2017 17.177.000 38.35%
2018 22.943.000 25.13%
2019 17.934.000 -27.93%
2020 21.220.000 15.49%
2021 26.907.000 21.14%
2022 20.636.000 -30.39%
2023 30.008.000 31.23%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

LeMaitre Vascular, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 1 0%
2017 1 0%
2018 1 100%
2019 1 0%
2020 1 100%
2021 1 0%
2022 1 0%
2023 1 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

LeMaitre Vascular, Inc. Free Cashflow
Year Free Cashflow Growth
2004 119.000
2005 -2.215.000 105.37%
2006 -1.495.000 -48.16%
2007 -3.219.000 53.56%
2008 -157.000 -1950.32%
2009 3.815.000 104.12%
2010 4.494.000 15.11%
2011 1.085.000 -314.19%
2012 3.397.000 68.06%
2013 2.491.000 -36.37%
2014 4.323.000 42.38%
2015 9.148.000 52.74%
2016 14.053.000 34.9%
2017 16.451.000 14.58%
2018 16.452.000 0.01%
2019 10.418.000 -57.92%
2020 31.818.000 67.26%
2021 30.220.000 -5.29%
2022 22.149.000 -36.44%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

LeMaitre Vascular, Inc. Operating Cashflow
Year Operating Cashflow Growth
2004 1.682.000
2005 -1.202.000 239.93%
2006 -526.000 -128.52%
2007 -1.826.000 71.19%
2008 581.000 414.29%
2009 5.440.000 89.32%
2010 7.052.000 22.86%
2011 3.170.000 -122.46%
2012 4.722.000 32.87%
2013 5.388.000 12.36%
2014 5.512.000 2.25%
2015 11.438.000 51.81%
2016 16.896.000 32.3%
2017 22.868.000 26.12%
2018 19.506.000 -17.24%
2019 14.179.000 -37.57%
2020 34.800.000 59.26%
2021 35.102.000 0.86%
2022 25.378.000 -38.32%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

LeMaitre Vascular, Inc. Capital Expenditure
Year Capital Expenditure Growth
2004 1.563.000
2005 1.013.000 -54.29%
2006 969.000 -4.54%
2007 1.393.000 30.44%
2008 738.000 -88.75%
2009 1.625.000 54.58%
2010 2.558.000 36.47%
2011 2.085.000 -22.69%
2012 1.325.000 -57.36%
2013 2.897.000 54.26%
2014 1.189.000 -143.65%
2015 2.290.000 48.08%
2016 2.843.000 19.45%
2017 6.417.000 55.7%
2018 3.054.000 -110.12%
2019 3.761.000 18.8%
2020 2.982.000 -26.12%
2021 4.882.000 38.92%
2022 3.229.000 -51.19%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

LeMaitre Vascular, Inc. Equity
Year Equity Growth
2001 1.710.000
2002 8.024.000 78.69%
2004 14.813.000 45.83%
2005 18.536.000 20.09%
2006 50.699.000 63.44%
2007 48.586.000 -4.35%
2008 45.748.000 -6.2%
2009 48.213.000 5.11%
2010 52.356.000 7.91%
2011 52.088.000 -0.51%
2012 52.888.000 1.51%
2013 56.562.000 6.5%
2014 68.207.000 17.07%
2015 77.884.000 12.42%
2016 87.500.000 10.99%
2017 109.770.000 20.29%
2018 130.235.000 15.71%
2019 148.143.000 12.09%
2020 172.572.000 14.16%
2021 254.151.000 32.1%
2022 268.201.000 5.24%
2023 288.637.000 7.08%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

LeMaitre Vascular, Inc. Assets
Year Assets Growth
2001 12.162.000
2002 12.718.000 4.37%
2004 20.501.000 37.96%
2005 25.068.000 18.22%
2006 56.963.000 55.99%
2007 61.151.000 6.85%
2008 54.399.000 -12.41%
2009 56.906.000 4.41%
2010 63.274.000 10.06%
2011 59.687.000 -6.01%
2012 63.060.000 5.35%
2013 70.492.000 10.54%
2014 81.492.000 13.5%
2015 90.704.000 10.16%
2016 101.924.000 11.01%
2017 126.323.000 19.31%
2018 153.088.000 17.48%
2019 188.339.000 18.72%
2020 252.810.000 25.5%
2021 292.802.000 13.66%
2022 310.476.000 5.69%
2023 334.012.000 7.05%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

LeMaitre Vascular, Inc. Liabilities
Year Liabilities Growth
2001 5.044.000
2002 4.694.000 -7.46%
2004 5.688.000 17.48%
2005 6.532.000 12.92%
2006 6.264.000 -4.28%
2007 12.565.000 50.15%
2008 8.651.000 -45.24%
2009 8.693.000 0.48%
2010 10.918.000 20.38%
2011 7.599.000 -43.68%
2012 10.172.000 25.29%
2013 13.930.000 26.98%
2014 13.285.000 -4.86%
2015 12.820.000 -3.63%
2016 14.424.000 11.12%
2017 16.553.000 12.86%
2018 22.853.000 27.57%
2019 40.196.000 43.15%
2020 80.238.000 49.9%
2021 38.651.000 -107.6%
2022 42.275.000 8.57%
2023 45.375.000 6.83%

LeMaitre Vascular, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
8.33
Net Income per Share
1.22
Price to Earning Ratio
45x
Price To Sales Ratio
6.61x
POCF Ratio
67.21
PFCF Ratio
101.7
Price to Book Ratio
4.25
EV to Sales
6.61
EV Over EBITDA
34.34
EV to Operating CashFlow
67.14
EV to FreeCashFlow
101.61
Earnings Yield
0.02
FreeCashFlow Yield
0.01
Market Cap
1,23 Bil.
Enterprise Value
1,23 Bil.
Graham Number
18.9
Graham NetNet
4.39

Income Statement Metrics

Net Income per Share
1.22
Income Quality
0.92
ROE
0.1
Return On Assets
0.09
Return On Capital Employed
0.12
Net Income per EBT
0.76
EBT Per Ebit
1.08
Ebit per Revenue
0.19
Effective Tax Rate
0.24

Margins

Sales, General, & Administrative to Revenue
0.16
Research & Developement to Revenue
0.09
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.65
Operating Profit Margin
0.19
Pretax Profit Margin
0.2
Net Profit Margin
0.16

Dividends

Dividend Yield
0.01
Dividend Yield %
1.02
Payout Ratio
0.33
Dividend Per Share
0.56

Operating Metrics

Operating Cashflow per Share
0.82
Free CashFlow per Share
0.54
Capex to Operating CashFlow
-0.34
Capex to Revenue
-0.03
Capex to Depreciation
-0.89
Return on Invested Capital
0.08
Return on Tangible Assets
0.12
Days Sales Outstanding
46.98
Days Payables Outstanding
24.28
Days of Inventory on Hand
312.07
Receivables Turnover
7.77
Payables Turnover
15.03
Inventory Turnover
1.17
Capex per Share
-0.28

Balance Sheet

Cash per Share
4,36
Book Value per Share
12,96
Tangible Book Value per Share
8.06
Shareholders Equity per Share
12.96
Interest Debt per Share
0.77
Debt to Equity
0.06
Debt to Assets
0.05
Net Debt to EBITDA
-0.03
Current Ratio
6.28
Tangible Asset Value
0,18 Bil.
Net Current Asset Value
0,14 Bil.
Invested Capital
0.06
Working Capital
0,15 Bil.
Intangibles to Total Assets
0.33
Average Receivables
0,03 Bil.
Average Payables
0,00 Bil.
Average Inventory
55009000
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

LeMaitre Vascular, Inc. Dividends
Year Dividends Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 1 0%
2023 1 0%

LeMaitre Vascular, Inc. Profile

About LeMaitre Vascular, Inc.

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

CEO
Mr. George W. LeMaitre
Employee
614
Address
63 Second Avenue
Burlington, 01803

LeMaitre Vascular, Inc. Executives & BODs

LeMaitre Vascular, Inc. Executives & BODs
# Name Age
1 Mr. Joseph P. Pellegrino Jr.
Chief Financial Officer, Treasurer, Secretary & Director
70
2 Ms. Kimberly L. Cieslak
Vice President of Marketing
70
3 Dr. George D. LeMaitre
Founder and Chairman of Scientific Advisory Board
70
4 Mr. David C. Hissong
General Counsel
70
5 Mr. Ryan H. Connelly
Senior Vice President of Advanced Manufacturing Engineering
70
6 Mr. Daniel J. Mumford
Director of Human Resources
70
7 Mr. Andrew Hodgkinson
Senior Vice President of Clinical, Regulatory & Quality Affairs
70
8 Mr. David B. Roberts
President & Director
70
9 Mr. Trent G. Kamke
Senior Vice President of Operations
70
10 Mr. George W. LeMaitre
Chairman & Chief Executive Officer
70

LeMaitre Vascular, Inc. Competitors